Tratamiento farmacológico del síndrome coronario crónico

  1. García Rivas, S. 1
  2. Viéitez Flórez, J.M. 1
  3. Monteagudo Ruiz, J.M. 1
  4. Zamorano Gómez, J.L. 1
  1. 1 Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades cardiovasculares (III)

Serie: 13

Número: 37

Páginas: 2134-2144

Tipo: Artículo

DOI: 10.1016/J.MED.2021.06.021 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La estrategia farmacológica en pacientes con angina estable y síndrome coronario crónico tiene como objetivos principales el control de los síntomas y la prevención de eventos cardiovasculares. En la prevención de la angina a largo plazo, muchas veces es necesaria la asociación de fármacos antiisquémicos de primera y segunda línea, y la elección del tratamiento debe dirigirse de forma individualizada, teniendo en cuenta las comorbilidades del paciente y el mecanismo subyacente a la isquemia. El tratamiento antitrombótico constituye el pilar fundamental en la prevención de eventos, siendo necesaria una doble terapia antiagregante en determinados escenarios clínicos, especialmente en la prevención de trombosis del stent tras revascularización percutánea. El tratamiento hipolipemiante, así como otra serie de fármacos que se han asociado con un beneficio en la morbimortalidad cardiovascular, forman también parte de la estrategia terapéutica en estos pacientes. Por último, la revascularización percutánea o quirúrgica debe considerarse cuando persisten síntomas importantes, a pesar del tratamiento médico, y cuando se considera un beneficio pronóstico de la misma.

Referencias bibliográficas

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C. 2019 ESC Guidelines for the diagnosis and ma-nagement of chronic coronary syndromes. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77.
  • Thadani U. Management of stable angina - current guidelines: a critical appraisal. Cardiovasc Drugs Ther. 2016;30(4):419-26.
  • López Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H. Documento de consenso de expertos sobre bloqueadores de los receptores β-adrenérgicos. Rev Esp Cardiol. 2005;58(1):65-90.
  • Ferrari R, Camici PG, Crea F, Danchin N, Fox K, Maggioni AP. A “diamond” approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120-32.
  • López de Sá E, Estévez Á, Onaindía J, Rubio R, López Sendón J. Papel de los nitratos en el tratamiento de la enfermedad cardiovascular. Rev Esp Cardiol. 2006;6:41A-50A.
  • Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091-9.
  • Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and leftventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo controlled trial. Lancet. 2008;372(9641):807-16.
  • Jiang J, Li Y, Zhou Y, Li X, Li H, Tang B. Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open label, randomized, controlled study. Int J Cardiol. 2016;224:183-7.
  • Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska Prokopczuk E, Buros JL. Efficacy of ranolazine in patients with chronic angina: observations from the randomized, double blind, placebo controlled MERLIN–TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53(17):1510-6.
  • Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol. 2013;61(20):2038-45.
  • McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an antianginal agent. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):266-72.
  • Vidal Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016 29;388(10056):2142-52.
  • Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
  • Swedberg K, Komajda M, B öhm M, Borer JS, Ford I, Dubost Brama A. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo controlled study. Lancet. 2010;376(9744):875-85.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribu-tion of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
  • Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-52.
  • Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta analysis. Cardiology. 2011;120(2):59-72.
  • Antithrombotic Trialists ’ Collaboration. Collaborative meta analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
  • Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B. Expert consensus document on the use of antiplatelet agents. Rev Esp Cardiol. 2004;57(10):963-80.
  • Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019 17;381(16):1524-34.
  • Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardiothoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260.
  • Palmerini T, Benedetto U, Bacchi Reggiani L, Riva DD, Biondi Zoccai G, Feres F. Mortality in patients treated with extended duration dual antiplatelet therapy after drug eluting stent implantation: a pairwise and Bayesian network meta analysis of randomised trials. Lancet. 2015; 385(9985):2371-82.
  • Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65(20):2211-21.
  • Collet JP, Thiele H, Barbato E, Barth élémy O, Bauersachs J, Bhatt DL. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367.
  • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88.
  • Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbal án R, Špinar J. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 10;137(15):1571-82.
  • Neumann FJ, Sousa Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 07;40(2):87-165.
  • Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O ’Brien SM, Boden WE. Initial invasive or conservative strategy for stable coronary disease. New Engl J Med. 2020;382(15):1395-407
Fuente de los datos: Dialnet